<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153225">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142790</url>
  </required_header>
  <id_info>
    <org_study_id>LY-TM-LPS-2014-02</org_study_id>
    <nct_id>NCT02142790</nct_id>
  </id_info>
  <brief_title>Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label Phase II study in  patients with metastatic breast cancer to evaluate
      the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection
      compared to 3-weekly regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel liposome injection weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel liposome injection 100mg/m2  administered by intravenous on day1 and  day8 of a  21-day cycle for 4-6 cycles or till progression or intolerable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel liposome injection every 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a  21-day cycle for 4-6 cycles or till progression or intolerable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel liposome injection</intervention_name>
    <arm_group_label>paclitaxel liposome injection weekly</arm_group_label>
    <arm_group_label>paclitaxel liposome injection every 3 weeks</arm_group_label>
    <other_name>LIPUSU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or Male &gt;18 years of age and &lt; 70years of age, If female of childbearing
             potential, pregnancy test is negative before first dose of study drug and agree to
             use an acceptable method of birth control to avoid pregnancy for the duration of the
             study

          -  Stage IV disease

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  Patients must not be a candidate for Herceptin therapy

          -  Suitable for the treatment with paclitaxel as single agent regimen (prior
             chemotherapy for metastatic disease was allowed. If a taxane was part of the adjuvant
             regimen, at least one year should have transpired since completion of taxane regimen
             and if Her2+ patient, Herceptin therapy will be allowed.

          -  Patient has the following values at Baseline: Absolute neutrophil count ≥ 1.5 x
             10^9cells/L; platelets ≥ 100 x 10^9 cells/L; hemoglobin ≥ 10 g/dL. Aspartate
             transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x upper limit
             of normal range (ULN); total bilirubin ≤ 1.5ULN; creatinine ≤ 1.5 mg/dL.

          -  Informed consent has been obtained.

        Exclusion Criteria:

          -  Parenchymal brain metastases.

          -  History of other malignancy within the last 3 years

          -  New York Heart Association (NYHA) Grade 2 or greater congestive heart failure,history
             of myocardial infarction or unstable angina or new occured angina  within 6 months
             prior to study enrollment.

          -  Concurrent other anticancer therapy.

          -  History of serious organic disorders (including active infection or Cardiovascular
             disease), serious hepatic disease, serious blood coagulation diseases, cachexia

          -  Sensory neuropathy of &gt; Grade 1 at baseline.

          -  Patients with prior hypersensitivity to paclitaxel

          -  Pregnant or nursing women

          -  enrolled in a different clinical study

          -  No psychiatric illness and other situations that would limit compliance of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quchang Ouyang, MD</last_name>
    <email>oyqc1969@126.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
